Asad Bhatty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asad Bhatty has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Chris P Gale
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds
5 shared publications- Chris Wilkinson
Hull York Medical School, University of York, York, UK
5 shared publications - Gorav Batra
Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
4 shared publications Alar Irs
Tartu Univ Hosp, Heart Clin, Tartu, Estonia
3 shared publications- Barbara Casadei
Imperial College London
3 shared publications Dragos Vinereanu
Unidade Local Saude Coimbra, Cardiol Dept, Coimbra, Portugal
3 shared publications
Latest Publications
- Open Access
- 27 May 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (4) , 100592
A FeAsibility items Checklist for assessing implementation characTeristics of patient-reported Outcome measures in Research, Regulation and Routine clinical care (FACTOR3): Development and evaluation
- 27 May 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (4) , 100592
Open AccessA FeAsibility items Checklist for assessing implementation characTeristics of patient-reported Outcome measures in Research, Regulation and Routine clinical care (FACTOR3): Development and evaluation
- Open Access
- 18 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (3) , 473-487
Psychometric properties of health-related quality of life patient reported outcome measures for common cardiovascular conditions: a scoping review and COSMIN analysis
Aims: Health-related quality of life (HRQoL) is an important measure of disease status and represents a holistic approach to delivering patient-centered care. We conducted a scoping review of HRQoL patient reported outcome measures (PROMs) for cardiovascular diseases (CVDs) and evaluated their psychometric properties. Methods and results: Randomized trials and observational studies that developed and validated HRQoL PROMs for adults with ischaemic heart disease (IHD), aortic stenosis (AS), atrial fibrillation (AF), heart failure (HF), or generic CVD were included, published from inception of databases to 8 February 2025 using PubMed, Web of Science, and Embase. Independent reviewers selected and extracted the psychometric properties of each PROM in accordance with the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) checklist: content validity, reliability, internal consistency, structural validity, criterion/convergent, cross-cultural validity, measurement error, hypothesis testing, and responsiveness. Each PROM was graded using the Grading of Recommendations Assessment, Development, and Evaluation approach. Of 9430 articles, 220 studies for 38 different PROMs were included (HF n = 17, 45%; AF n = 11, 29%; IHD n = 7, 18%; generic n = 2, 5%; AS n = 1, 3%). Eleven PROMs (29%) satisfied all nine COSMIN criteria; the majority (n = 19, 50%) required further validation and eight were deemed inadequate for clinical use (21%). Conclusion: This scoping review of HRQoL PROMs in individuals with common CVDs found evidence that many PROMs do not fulfill all nine COSMIN criteria for methodological quality, and for some CVDs there is a limited choice of suitable PROMs for HRQoL measurement. There is an opportunity to improve HRQoL evaluation for use within routine care and research.
- 18 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (3) , 473-487
Open AccessPsychometric properties of health-related quality of life patient reported outcome measures for common cardiovascular conditions: a scoping review and COSMIN analysis
Aims: Health-related quality of life (HRQoL) is an important measure of disease status and represents a holistic approach to delivering patient-centered care. We conducted a scoping review of HRQoL patient reported outcome measures (PROMs) for cardiovascular diseases (CVDs) and evaluated their psychometric properties. Methods and results: Randomized trials and observational studies that developed and validated HRQoL PROMs for adults with ischaemic heart disease (IHD), aortic stenosis (AS), atrial fibrillation (AF), heart failure (HF), or generic CVD were included, published from inception of databases to 8 February 2025 using PubMed, Web of Science, and Embase. Independent reviewers selected and extracted the psychometric properties of each PROM in accordance with the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) checklist: content validity, reliability, internal consistency, structural validity, criterion/convergent, cross-cultural validity, measurement error, hypothesis testing, and responsiveness. Each PROM was graded using the Grading of Recommendations Assessment, Development, and Evaluation approach. Of 9430 articles, 220 studies for 38 different PROMs were included (HF n = 17, 45%; AF n = 11, 29%; IHD n = 7, 18%; generic n = 2, 5%; AS n = 1, 3%). Eleven PROMs (29%) satisfied all nine COSMIN criteria; the majority (n = 19, 50%) required further validation and eight were deemed inadequate for clinical use (21%). Conclusion: This scoping review of HRQoL PROMs in individuals with common CVDs found evidence that many PROMs do not fulfill all nine COSMIN criteria for methodological quality, and for some CVDs there is a limited choice of suitable PROMs for HRQoL measurement. There is an opportunity to improve HRQoL evaluation for use within routine care and research.
Outcome measures for randomised clinical trials and multicentre observational studies of cardiovascular diseases published in major clinical journals: systematic review and evidence mapping
Background: Outcome measure choice and definition can determine the result of the study. We describe outcome measures and their definitions for cardiovascular studies in highly cited medical journals. Methods: Cardiovascular phase III or IV randomised clinical trials (RCTs) or multicentre observational studies published in the New England Journal of Medicine , Lancet or Journal of the American Medical Association between 1 January 2013 and 6 June 2024 from Embase and Ovid Medline were included. Two independent reviewers selected the studies and extracted the primary and secondary outcome measures from each publication. Results: 386 studies (83% RCTs; 17% observational) representing 10 699 147 participants were included. Studies investigated coronary heart disease (51%), cardiomyopathy/heart failure (22%), heart rhythm disease (15%), valvular heart disease (11%) and ‘other’ cardiovascular diseases (1%), with 45% investigating a device and 48% funded by industry. The most frequently reported primary outcome measure was a composite (63%), the most frequent component of which was myocardial infarction (58%). The use of a composite for the primary outcome measure increased from 49% of studies in 2013 to a peak of 85% in 2018. From 2013 to 2023, the median number of secondary outcome measures per study increased for RCTs (3–8) and observational studies (0–7). Definitions for cardiovascular mortality, myocardial infarction and stroke varied across the studies. Conclusions: For cardiovascular studies published in highly cited journals, there has been an expansion in the use of primary composite outcome measures and secondary outcome measures, with heterogeneity in the definition of primary outcome measures. A standardised approach to the use of cardiovascular outcomes measures is required.
Outcome measures for randomised clinical trials and multicentre observational studies of cardiovascular diseases published in major clinical journals: systematic review and evidence mapping
Background: Outcome measure choice and definition can determine the result of the study. We describe outcome measures and their definitions for cardiovascular studies in highly cited medical journals. Methods: Cardiovascular phase III or IV randomised clinical trials (RCTs) or multicentre observational studies published in the New England Journal of Medicine , Lancet or Journal of the American Medical Association between 1 January 2013 and 6 June 2024 from Embase and Ovid Medline were included. Two independent reviewers selected the studies and extracted the primary and secondary outcome measures from each publication. Results: 386 studies (83% RCTs; 17% observational) representing 10 699 147 participants were included. Studies investigated coronary heart disease (51%), cardiomyopathy/heart failure (22%), heart rhythm disease (15%), valvular heart disease (11%) and ‘other’ cardiovascular diseases (1%), with 45% investigating a device and 48% funded by industry. The most frequently reported primary outcome measure was a composite (63%), the most frequent component of which was myocardial infarction (58%). The use of a composite for the primary outcome measure increased from 49% of studies in 2013 to a peak of 85% in 2018. From 2013 to 2023, the median number of secondary outcome measures per study increased for RCTs (3–8) and observational studies (0–7). Definitions for cardiovascular mortality, myocardial infarction and stroke varied across the studies. Conclusions: For cardiovascular studies published in highly cited journals, there has been an expansion in the use of primary composite outcome measures and secondary outcome measures, with heterogeneity in the definition of primary outcome measures. A standardised approach to the use of cardiovascular outcomes measures is required.
- Open Access
- 15 November 2024
- Vol. 46 (2) , 190-214
Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
Background and Aims Standardized definitions for outcome measures in randomized clinical trials and observational studies are essential for robust and valid evaluation of medical products, interventions, care, and outcomes. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) project of the European Society of Cardiology aimed to create international data standards for cardiovascular clinical study outcome measures.Methods The EuroHeart methods for data standard development were used. From a Global Cardiovascular Outcomes Consortium of 82 experts, five Working Groups were formed to identify and define key outcome measures for: cardiovascular disease (generic outcomes), acute coronary syndrome and percutaneous coronary intervention (ACS/PCI), atrial fibrillation (AF), heart failure (HF) and transcatheter aortic valve implantation (TAVI). A systematic review of the literature informed a modified Delphi method to reach consensus on a final set of variables. For each variable, the Working Group provided a definition and categorized the variable as mandatory (Level 1) or optional (Level 2) based on its clinical importance and feasibility.Results Across the five domains, 24 Level 1 (generic: 5, ACS/PCI: 8, AF: 2; HF: 5, TAVI: 4) and 48 Level 2 (generic: 18, ACS-PCI: 7, AF: 6, HF: 2, TAVI: 15) outcome measures were defined.Conclusions Internationally derived and endorsed definitions for outcome measures for a range of common cardiovascular diseases and interventions are presented. These may be used for data alignment to enable high-quality observational and randomized clinical research, audit, and quality improvement for patient benefit.
- 15 November 2024
- Vol. 46 (2) , 190-214
Open AccessDefinitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
Background and Aims Standardized definitions for outcome measures in randomized clinical trials and observational studies are essential for robust and valid evaluation of medical products, interventions, care, and outcomes. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) project of the European Society of Cardiology aimed to create international data standards for cardiovascular clinical study outcome measures.Methods The EuroHeart methods for data standard development were used. From a Global Cardiovascular Outcomes Consortium of 82 experts, five Working Groups were formed to identify and define key outcome measures for: cardiovascular disease (generic outcomes), acute coronary syndrome and percutaneous coronary intervention (ACS/PCI), atrial fibrillation (AF), heart failure (HF) and transcatheter aortic valve implantation (TAVI). A systematic review of the literature informed a modified Delphi method to reach consensus on a final set of variables. For each variable, the Working Group provided a definition and categorized the variable as mandatory (Level 1) or optional (Level 2) based on its clinical importance and feasibility.Results Across the five domains, 24 Level 1 (generic: 5, ACS/PCI: 8, AF: 2; HF: 5, TAVI: 4) and 48 Level 2 (generic: 18, ACS-PCI: 7, AF: 6, HF: 2, TAVI: 15) outcome measures were defined.Conclusions Internationally derived and endorsed definitions for outcome measures for a range of common cardiovascular diseases and interventions are presented. These may be used for data alignment to enable high-quality observational and randomized clinical research, audit, and quality improvement for patient benefit.
- Open Access
- 9 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (7) , 900-909
Standardized and hierarchically classified heart failure and complementary disease monitoring outcome measures: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)
Aims: The lack of standardized definitions for heart failure outcome measures limits the ability to reliably assess the effectiveness of heart failure therapies. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) aimed to produce a catalogue of internationally endorsed data definitions for heart failure outcome measures. Methods and results: Following the EuroHeart methods for the development of cardiovascular data standards, a working group was formed of representatives from the European Society of Cardiology Heart Failure Association and other leading heart failure experts. A systematic review of observational and randomized clinical trials identified current outcome measures, which was supplemented by clinical practice guidelines and existing registries for contemporary definitions. A modified Delphi process was employed to gain consensus for variable inclusion and whether collection should be mandatory (Level 1) or optional (Level 2) within EuroHeart. In addition, a set of complementary outcome measures were identified by the working group as of scientific and clinical importance for longitudinal monitoring for people with heart failure. Five Level 1 and two Level 2 outcome measures were selected and defined, alongside five complementary monitoring outcomes for patients with heart failure. Conclusion: We present a structured, hierarchical catalogue of internationally endorsed heart failure outcome measures. This will facilitate quality improvement, high quality observational research, registry-based trials, and post-market surveillance of medical devices.
- 9 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (7) , 900-909
Open AccessStandardized and hierarchically classified heart failure and complementary disease monitoring outcome measures: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)
Aims: The lack of standardized definitions for heart failure outcome measures limits the ability to reliably assess the effectiveness of heart failure therapies. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) aimed to produce a catalogue of internationally endorsed data definitions for heart failure outcome measures. Methods and results: Following the EuroHeart methods for the development of cardiovascular data standards, a working group was formed of representatives from the European Society of Cardiology Heart Failure Association and other leading heart failure experts. A systematic review of observational and randomized clinical trials identified current outcome measures, which was supplemented by clinical practice guidelines and existing registries for contemporary definitions. A modified Delphi process was employed to gain consensus for variable inclusion and whether collection should be mandatory (Level 1) or optional (Level 2) within EuroHeart. In addition, a set of complementary outcome measures were identified by the working group as of scientific and clinical importance for longitudinal monitoring for people with heart failure. Five Level 1 and two Level 2 outcome measures were selected and defined, alongside five complementary monitoring outcomes for patients with heart failure. Conclusion: We present a structured, hierarchical catalogue of internationally endorsed heart failure outcome measures. This will facilitate quality improvement, high quality observational research, registry-based trials, and post-market surveillance of medical devices.
- 12 April 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 10 (5) , 386-390
Cohort profile: the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)—acute coronary syndrome and percutaneous coronary intervention
The European Unified Registries On Heart care Evaluation And Randomized Trials (EuroHeart) aims to improve the quality of care and clinical outcomes for patients with cardiovascular disease. The collaboration of acute coronary syndrome/percutaneous coronary intervention (ACS/PCI) registries is operational in seven vanguard European Society of Cardiology member countries. Adults admitted to hospitals with ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) are included, and individual patient-level data collected and aligned according to the internationally agreed EuroHeart data standards for ACS/PCI. The registries provide up to 155 variables spanning patient demographics and clinical characteristics, in-hospital care, in-hospital outcomes, and discharge medications. After performing statistical analyses on patient data, participating countries transfer aggregated data to EuroHeart for international reporting. Between 1st January 2022 and 31st December 2022, 40 021 admissions (STEMI 46.7%, NSTEMI 53.3%) were recorded from 192 hospitals in the seven vanguard countries: Estonia, Hungary, Iceland, Portugal, Romania, Singapore, and Sweden. The mean age for the cohort was 67.9 (standard deviation 12.6) years, and it included 12 628 (31.6%) women. The EuroHeart collaboration of ACS/PCI registries prospectively collects and analyses individual data for ACS and PCI at a national level, after which aggregated results are transferred to the EuroHeart Data Science Centre. The collaboration will expand to other countries and provide continuous insights into the provision of clinical care and outcomes for patients with ACS and undergoing PCI. It will serve as a unique international platform for quality improvement, observational research, and registry-based clinical trials.
- 12 April 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 10 (5) , 386-390
Cohort profile: the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)—acute coronary syndrome and percutaneous coronary intervention
The European Unified Registries On Heart care Evaluation And Randomized Trials (EuroHeart) aims to improve the quality of care and clinical outcomes for patients with cardiovascular disease. The collaboration of acute coronary syndrome/percutaneous coronary intervention (ACS/PCI) registries is operational in seven vanguard European Society of Cardiology member countries. Adults admitted to hospitals with ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) are included, and individual patient-level data collected and aligned according to the internationally agreed EuroHeart data standards for ACS/PCI. The registries provide up to 155 variables spanning patient demographics and clinical characteristics, in-hospital care, in-hospital outcomes, and discharge medications. After performing statistical analyses on patient data, participating countries transfer aggregated data to EuroHeart for international reporting. Between 1st January 2022 and 31st December 2022, 40 021 admissions (STEMI 46.7%, NSTEMI 53.3%) were recorded from 192 hospitals in the seven vanguard countries: Estonia, Hungary, Iceland, Portugal, Romania, Singapore, and Sweden. The mean age for the cohort was 67.9 (standard deviation 12.6) years, and it included 12 628 (31.6%) women. The EuroHeart collaboration of ACS/PCI registries prospectively collects and analyses individual data for ACS and PCI at a national level, after which aggregated results are transferred to the EuroHeart Data Science Centre. The collaboration will expand to other countries and provide continuous insights into the provision of clinical care and outcomes for patients with ACS and undergoing PCI. It will serve as a unique international platform for quality improvement, observational research, and registry-based clinical trials.
- Open Access
- 1 February 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 10 (2) , 105-107
Defining the need for cardiovascular event definitions
There has been a transformation in clinical care and outcomes for patients with cardiovascular disease in recent times. This has largely been enabled by the robust evaluation of the safety and efficacy of new pharmaceutical agents and health technologies in randomized clinical trials (RCT). Integral to this progress is the judicious and a priori selection and definition of key cardiovascular outcome measures against which an intervention is assessed and evaluated.1
- 1 February 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 10 (2) , 105-107
Open AccessDefining the need for cardiovascular event definitions
There has been a transformation in clinical care and outcomes for patients with cardiovascular disease in recent times. This has largely been enabled by the robust evaluation of the safety and efficacy of new pharmaceutical agents and health technologies in randomized clinical trials (RCT). Integral to this progress is the judicious and a priori selection and definition of key cardiovascular outcome measures against which an intervention is assessed and evaluated.1